Janus Kinases (JAKs) Inhibitor Drug Global Market Report 2025
상품코드:1769631
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
자누스 키나아제(JAK) 억제제 시장 규모는 향후 수년간 급성장이 전망됩니다. 2029년에는 CAGR 11.5%로 성장할 전망이며, 99억 3,000만 달러로 성장이 예측됩니다. 예측 기간 성장의 원동력은 면역질환에 대한 치료 선택지 확대, 승인된 적응증 증가, 환자 인식 및 교육 향상, 치료 접근성 개선, 면역요법 중시 증가에 기인할 것으로 보입니다. 주요 동향으로는 경구요법으로의 전환, 디지털 치료약의 통합, 전략적 파트너십과 제휴, 병용요법 발전, 연구개발에 대한 투자의 고조 등을 들 수 있습니다.
자가면역 질환의 유병률 증가는 자누스 키나아제(JAK) 억제제 시장의 향후 성장을 견인할 것으로 예측됩니다. 자가면역 질환은 면역계가 실수로 신체의 건강한 세포나 조직을 공격함으로써 발병합니다. 이러한 질환의 증가는 유전적 요인의 영향을 받고 있으며, 특정 소인에 의해 면역기능 장애를 일으키기 쉬워지고 있습니다. JAK 저해제는 면역 신호 전달에 관여하는 특정 효소를 표적으로 차단함으로써 염증을 억제하고 면역 개재성 조직 손상을 방지합니다. 예를 들어 2024년 6월 호주 보건복지연구소의 보고에 따르면 호주에서 류마티스 관절염으로 인한 입원 환자 수는 2021-2022년 1만 명에 달했으며, 전년 8,000명에서 25% 증가했습니다. 그 결과 자가면역 질환 유병률 증가가 JAK 억제제 수요를 촉진하고 있습니다.
자누스 키나아제(JAK) 억제제 시장에서 사업을 전개하는 주요 기업은 치료 적응 확대, 시장 진입 가속, 경쟁력 강화를 위해 약사 승인 취득에 주력하고 있습니다. 약사 승인은 특정 병세에 대한 안전성 및 유효성을 확인한 후 의약품의 판매 및 마케팅을 허가하는 보건당국에 의한 공적 인가를 말합니다. 예를 들어 2025년 4월 미국의 바이오의약품 회사인 애비 잉크는 경구 JAK1 선택적 저해제인 RINVOQ(우파다시티닙)에 대해 성인의 거대세포성동맥염(GCA) 치료제로서 FDA 승인을 취득했습니다. 우파다시티닙은 면역매개성 질환 및 염증성 질환에 관여하는 염증성 사이토카인의 신호를 전달하는 JAK-STAT 신호전달 경로를 저해함으로써 작용합니다. 이번 승인은 종종 중대한 부작용을 동반하는 글루코코르티코이드에 대한 의존을 줄이고, GCA 관리에 있어 중요한 암메트 니즈에 대응해 환자의 전귀를 개선하는 귀중한 새로운 치료 선택지를 제공하는 것입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 자누스 키나아제(JAK) 억제제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 자누스 키나아제(JAK) 억제제 시장 : 성장률 분석
세계의 자누스 키나아제(JAK) 억제제 시장 실적 : 규모 및 성장(2019-2024년)
세계의 자누스 키나아제(JAK) 억제제 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 자누스 키나아제(JAK) 억제제 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 자누스 키나아제(JAK) 억제제 시장 : 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
JAK1 억제제
JAK2 억제제
JAK3 억제제
기타 유형
세계의 자누스 키나아제(JAK) 억제제 시장 : 약제 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
선택적 JAK 억제제
비선택적 JAK 억제제
경구 JAK 억제제
기타 약물 유형
세계의 자누스 키나아제(JAK) 억제제 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
오랄
주사제
주제
세계의 자누스 키나아제(JAK) 억제제 시장 : 용도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
류마티스 관절
건선성 관절염
염증성 장질환
아토피 피부염
궤양성 대장염
세계의 자누스 키나아제(JAK) 억제제 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원
홈케어
전문 클리닉
기타 최종 사용자
세계의 자누스 키나아제(JAK) 억제제 시장 : JAK1 억제제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
필고티닙
우파다시티닙
이타시티닙
아브로시티닙
브레포시티닙
세계의 자누스 키나아제(JAK) 억제제 시장 : JAK2 억제제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
페드라티닙
파크리티닙
모메로티닙
간드티닙
NS-018
세계의 자누스 키나아제(JAK) 억제제 시장 : JAK3 억제제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
토파시티닙
PF-06651600
리틀시티닙
세계의 자누스 키나아제(JAK) 억제제 시장 : 기타 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
발리시티닙
룩소리티닙
오크라시티닙
델고시티닙
페피시티닙
제7장 지역별 및 국가별 분석
세계의 자누스 키나아제(JAK) 억제제 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 자누스 키나아제(JAK) 억제제 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
자누스 키나아제(JAK) 억제제 시장 : 경쟁 구도
자누스 키나아제(JAK) 억제제 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Johnson & Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Bristol-Myers Squibb Company
AstraZeneca PLC
GlaxoSmithKline plc
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Amgen Inc.
Regeneron Pharmaceuticals Inc.
Astellas Pharma Inc.
Vertex Pharmaceuticals Incorporated
Incyte Corporation
Galapagos NV
Theravance Biopharma Inc.
Celon Pharma SA
Aclaris Therapeutics Inc.
Arcutis Biotherapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
자누스 키나아제(JAK) 억제제 시장(2029년) : 새로운 기회를 제공하는 국가
자누스 키나아제(JAK) 억제제 시장(2029년) : 새로운 기회를 제공하는 부문
자누스 키나아제(JAK) 억제제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Janus kinase (JAK) inhibitor drugs are medications designed to block the activity of Janus kinases-enzymes that play a key role in immune system signaling and inflammatory pathways. By inhibiting these enzymes, JAK inhibitors help control overactive immune responses, making them effective in the treatment of autoimmune and inflammatory disorders.
The primary types of Janus kinase (JAK) inhibitors include JAK1, JAK2, JAK3 inhibitors, and other variants. JAK1 inhibitors specifically target the JAK1 enzyme, which is critical in immune cell signaling, and are widely used for managing conditions such as rheumatoid arthritis and atopic dermatitis. These drugs are available in several forms, including selective and non-selective inhibitors, and are administered via oral, injectable, or topical routes. Key therapeutic applications span rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, ulcerative colitis, and atopic dermatitis. The end users include hospitals, home care settings, specialty clinics, and other healthcare facilities.
The janus kinases JAKs inhibitor drug market research report is one of a series of new reports from The Business Research Company that provides janus kinases JAKs inhibitor drug market statistics, including janus kinases JAKs inhibitor drug industry global market size, regional shares, competitors with a janus kinases JAKs inhibitor drug market share, detailed janus kinases JAKs inhibitor drug market segments, market trends and opportunities, and any further data you may need to thrive in the janus kinases JAKs inhibitor drug industry. This janus kinases JAKs inhibitor drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The janus kinases (JAKs) inhibitor drug market size has grown rapidly in recent years. It will grow from $5.74 billion in 2024 to $6.42 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. The growth during the historic period was driven by the increasing prevalence of autoimmune diseases, expansion of Janus kinase (JAK) inhibitors' applications beyond rheumatoid arthritis, the aging global population, and favorable reimbursement policies supporting wider access to treatment.
The janus kinases (JAKs) inhibitor drug market size is expected to see rapid growth in the next few years. It will grow to $9.93 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period is expected to be driven by expanding treatment options for immunological diseases, a rising number of approved indications, increased patient awareness and education, improved accessibility to therapies, and a growing emphasis on immunotherapy. Key trends include a shift toward oral therapies, integration of digital therapeutics, strategic partnerships and collaborations, advances in combination therapies, and heightened investment in research and development.
The rising prevalence of autoimmune diseases is expected to drive the growth of the Janus kinase (JAK) inhibitor drug market going forward. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells and tissues. This increasing prevalence is influenced by genetic factors, as certain predispositions make individuals more susceptible to immune dysfunction. JAK inhibitors target and block specific enzymes involved in immune signaling, thereby reducing inflammation and preventing immune-mediated tissue damage. For instance, in June 2024, a report by the Australian Institute of Health and Welfare revealed that hospitalizations for rheumatoid arthritis in Australia rose to 10,000 in 2021-22, a 25% increase from 8,000 the previous year, corresponding to 39 hospitalizations per 100,000 population. Consequently, the growing prevalence of autoimmune diseases is propelling demand for JAK inhibitor drugs.
Major companies operating in the Janus kinase (JAK) inhibitor drug market are focusing on securing regulatory approvals to expand therapeutic indications, accelerate market entry, and strengthen their competitive position. Regulatory approvals are official authorizations granted by health authorities permitting the marketing and sale of drugs after confirming their safety and efficacy for specific medical conditions. For example, in April 2025, AbbVie Inc., a US-based biopharmaceutical company, received FDA approval for RINVOQ (upadacitinib), an oral JAK1-selective inhibitor, for treating adults with giant cell arteritis (GCA). Upadacitinib works by disrupting the JAK-STAT signaling pathway, which transmits signals from pro-inflammatory cytokines involved in immune-mediated and inflammatory diseases. This approval provides a valuable new treatment option that reduces dependence on glucocorticoids-often linked to significant side effects-thus addressing a critical unmet need in GCA management and improving patient outcomes.
In July 2022, GSK plc, a UK-based pharmaceutical and biotechnology company, acquired Sierra Oncology for $1.9 billion. This acquisition aims to strengthen GSK's specialty medicines portfolio by gaining access to momelotinib, a differentiated late-stage therapy that addresses significant unmet medical needs in myelofibrosis patients with anemia. The deal expands GSK's capabilities in hematology and offers meaningful new benefits to patients. Sierra Oncology, based in the US, develops momelotinib, a selective oral inhibitor of Janus kinases (JAK1 and JAK2) and ACVR1, specifically for treating myelofibrosis.
Major players in the janus kinases (jaks) inhibitor drug market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Galapagos NV, Theravance Biopharma Inc., Celon Pharma S.A., Aclaris Therapeutics Inc., Arcutis Biotherapeutics Inc., Dizal (Jiangsu) Pharmaceutical Co. Ltd., Reistone Biopharma Co. Ltd.
North America was the largest region in the janus kinases (JAKs) inhibitor market in 2024. The regions covered in janus kinases (JAKs) inhibitor drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the janus kinases (JAKs) inhibitor drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The janus kinases (JAKs) inhibitor drug market consists of sales of oral tablets, oral capsules, topical formulations, injectable forms, and additional JAK inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Janus Kinases (JAKs) Inhibitor Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on janus kinases (jaks) inhibitor drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for janus kinases (jaks) inhibitor drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The janus kinases (jaks) inhibitor drug market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: JAK1 Inhibitor; JAK2 Inhibitor; JAK3 Inhibitor; Other Types
2) By Drug Type: Selective JAK Inhibitors; Non-Selective JAK Inhibitors; Oral JAK Inhibitors; Other Drug Types
3) By Route of Administration: Oral; Injectable; Topical
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Janus Kinases (JAKs) Inhibitor Drug Market Characteristics
3. Janus Kinases (JAKs) Inhibitor Drug Market Trends And Strategies
4. Janus Kinases (JAKs) Inhibitor Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Janus Kinases (JAKs) Inhibitor Drug Growth Analysis And Strategic Analysis Framework
5.1. Global Janus Kinases (JAKs) Inhibitor Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Janus Kinases (JAKs) Inhibitor Drug Market Growth Rate Analysis
5.4. Global Janus Kinases (JAKs) Inhibitor Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Janus Kinases (JAKs) Inhibitor Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Janus Kinases (JAKs) Inhibitor Drug Total Addressable Market (TAM)
6. Janus Kinases (JAKs) Inhibitor Drug Market Segmentation
6.1. Global Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
JAK1 Inhibitor
JAK2 Inhibitor
JAK3 Inhibitor
Other Types
6.2. Global Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Selective JAK Inhibitors
Non-Selective JAK Inhibitors
Oral JAK Inhibitors
Other Drug Types
6.3. Global Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
Topical
6.4. Global Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Rheumatoid Arthritis
Psoriatic Arthritis
Inflammatory Bowel Disease
Atopic Dermatitis
Ulcerative Colitis
6.5. Global Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End Users
6.6. Global Janus Kinases (JAKs) Inhibitor Drug Market, Sub-Segmentation Of JAK1 Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Filgotinib
Upadacitinib
Itacitinib
Abrocitinib
Brepocitinib
6.7. Global Janus Kinases (JAKs) Inhibitor Drug Market, Sub-Segmentation Of JAK2 Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fedratinib
Pacritinib
Momelotinib
Gandotinib
NS-018
6.8. Global Janus Kinases (JAKs) Inhibitor Drug Market, Sub-Segmentation Of JAK3 Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tofacitinib
PF-06651600
Ritlecitinib
6.9. Global Janus Kinases (JAKs) Inhibitor Drug Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Baricitinib
Ruxolitinib
Oclacitinib
Delgocitinib
Peficitinib
7. Janus Kinases (JAKs) Inhibitor Drug Market Regional And Country Analysis
7.1. Global Janus Kinases (JAKs) Inhibitor Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Janus Kinases (JAKs) Inhibitor Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Janus Kinases (JAKs) Inhibitor Drug Market
8.1. Asia-Pacific Janus Kinases (JAKs) Inhibitor Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Janus Kinases (JAKs) Inhibitor Drug Market
9.1. China Janus Kinases (JAKs) Inhibitor Drug Market Overview
9.2. China Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Janus Kinases (JAKs) Inhibitor Drug Market
10.1. India Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Janus Kinases (JAKs) Inhibitor Drug Market
11.1. Japan Janus Kinases (JAKs) Inhibitor Drug Market Overview
11.2. Japan Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Janus Kinases (JAKs) Inhibitor Drug Market
12.1. Australia Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Janus Kinases (JAKs) Inhibitor Drug Market
13.1. Indonesia Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Janus Kinases (JAKs) Inhibitor Drug Market
14.1. South Korea Janus Kinases (JAKs) Inhibitor Drug Market Overview
14.2. South Korea Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Janus Kinases (JAKs) Inhibitor Drug Market
15.1. Western Europe Janus Kinases (JAKs) Inhibitor Drug Market Overview
15.2. Western Europe Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Janus Kinases (JAKs) Inhibitor Drug Market
16.1. UK Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Janus Kinases (JAKs) Inhibitor Drug Market
17.1. Germany Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Janus Kinases (JAKs) Inhibitor Drug Market
18.1. France Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Janus Kinases (JAKs) Inhibitor Drug Market
19.1. Italy Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Janus Kinases (JAKs) Inhibitor Drug Market
20.1. Spain Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Janus Kinases (JAKs) Inhibitor Drug Market
21.1. Eastern Europe Janus Kinases (JAKs) Inhibitor Drug Market Overview
21.2. Eastern Europe Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Janus Kinases (JAKs) Inhibitor Drug Market
22.1. Russia Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Janus Kinases (JAKs) Inhibitor Drug Market
23.1. North America Janus Kinases (JAKs) Inhibitor Drug Market Overview
23.2. North America Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Janus Kinases (JAKs) Inhibitor Drug Market
24.1. USA Janus Kinases (JAKs) Inhibitor Drug Market Overview
24.2. USA Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Janus Kinases (JAKs) Inhibitor Drug Market
25.1. Canada Janus Kinases (JAKs) Inhibitor Drug Market Overview
25.2. Canada Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Janus Kinases (JAKs) Inhibitor Drug Market
26.1. South America Janus Kinases (JAKs) Inhibitor Drug Market Overview
26.2. South America Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Janus Kinases (JAKs) Inhibitor Drug Market
27.1. Brazil Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Janus Kinases (JAKs) Inhibitor Drug Market
28.1. Middle East Janus Kinases (JAKs) Inhibitor Drug Market Overview
28.2. Middle East Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Janus Kinases (JAKs) Inhibitor Drug Market
29.1. Africa Janus Kinases (JAKs) Inhibitor Drug Market Overview
29.2. Africa Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Janus Kinases (JAKs) Inhibitor Drug Market Competitive Landscape And Company Profiles
30.1. Janus Kinases (JAKs) Inhibitor Drug Market Competitive Landscape
30.2. Janus Kinases (JAKs) Inhibitor Drug Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
31. Janus Kinases (JAKs) Inhibitor Drug Market Other Major And Innovative Companies
31.1. Bristol-Myers Squibb Company
31.2. AstraZeneca PLC
31.3. GlaxoSmithKline plc
31.4. Takeda Pharmaceutical Company Limited
31.5. Eli Lilly and Company
31.6. Amgen Inc.
31.7. Regeneron Pharmaceuticals Inc.
31.8. Astellas Pharma Inc.
31.9. Vertex Pharmaceuticals Incorporated
31.10. Incyte Corporation
31.11. Galapagos NV
31.12. Theravance Biopharma Inc.
31.13. Celon Pharma S.A.
31.14. Aclaris Therapeutics Inc.
31.15. Arcutis Biotherapeutics Inc.
32. Global Janus Kinases (JAKs) Inhibitor Drug Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Janus Kinases (JAKs) Inhibitor Drug Market
34. Recent Developments In The Janus Kinases (JAKs) Inhibitor Drug Market
35. Janus Kinases (JAKs) Inhibitor Drug Market High Potential Countries, Segments and Strategies
35.1 Janus Kinases (JAKs) Inhibitor Drug Market In 2029 - Countries Offering Most New Opportunities
35.2 Janus Kinases (JAKs) Inhibitor Drug Market In 2029 - Segments Offering Most New Opportunities
35.3 Janus Kinases (JAKs) Inhibitor Drug Market In 2029 - Growth Strategies
